Viewing Study NCT02103257


Ignite Creation Date: 2025-12-24 @ 6:41 PM
Ignite Modification Date: 2026-04-13 @ 7:43 PM
Study NCT ID: NCT02103257
Status: UNKNOWN
Last Update Posted: 2015-04-29
First Post: 2014-03-31
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Sponsor: Betta Pharmaceuticals Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module